Heartflow, Inc. Common Stock
NASDAQ:HTFL · NASDAQ Global Select
+$0.39 today
Vol 1.69M · Avg 1.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.8%
avg -5.1%
ROIC
-19.8%
avg -44.6%
ROA
-32.5%
avg -55.1%
Analysis
ROIC is currently the strongest return metric at -19.8% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Farquhar | President, Chief Executive Officer & Director | $1.44M | — | 53 | $496,835.00 | 0.58% |
Campbell Rogers FACC | Chief Medical Officer & Executive Vice President | $1.10M | — | 65 | $71,633.00 | 0.08% |
Vikram Verghese | Chief Financial Officer | $757,919.00 | — | 41 | $210,854.00 | 0.24% |
Angela Ahmad | Chief Legal & Compliance Officer | — | — | — | — | — |
Kathleen Carey | Senior Vice President of Operations | — | — | — | — | — |
John Henry Stevens | Co-Founder | — | — | 65 | $496,835.00 | 0.58% |
Mhairi L. Jones | Chief Accounting Officer | — | — | — | $31,083.00 | 0.04% |
Justin Cambra | Chief Technology Officer | — | — | — | — | — |
Nicholas S. Laudico | Vice President of Investor Relations | — | — | — | — | — |
Shivanth Bhaskaran | Chief Commercial Operations & Customer Success Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.05M
Sells
17
$123.61M
Net Sentiment
$122.55M
Net selling
Most Active
Farquhar John C.M.
6 transactions
1–10 of 18
Analysis
Insiders reported 1 buys worth $1.05M and 17 sells worth $123.61M over the last 12 months. That adds up to net selling of $122.55M. Farquhar John C.M. was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +24.4% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +24.4% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$5.33B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.07B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.97B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Disc Medicine, Inc.
NASDAQ:IRON
$2.68B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Surgery Partners, Inc.
NASDAQ:SGRY
$1.87B
Perrigo Company plc
NYSE:PRGO
$1.38B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.32B
Who manages HTFL?
Heartflow, Inc. Common Stock (HTFL) lists 10 active executives. The top listed executive is Vikram Verghese, Chief Financial Officer.
Are HTFL insiders buying or selling?
Recent insider activity shows net selling of $107.12M.
Explore More
Continue the stock analysis
Jump to another research area for this company.